AptarGroup (NYSE:ATR) 2026 Conference February 25, 2026 09:45 AM ET Company ParticipantsGeorge Staphos - Managing DirectorMary Skafidas - Head of Investor RelationsStephan Tanda - President and CEOGeorge StaphosStephan Tanda, CEO for the company, and Mary Skafidas, who does a wonderful job on Investor Relations. Here for Aptar, they unfortunately ran the gauntlet and ultimately could not be here live, but we are grateful that they're here virtually. That, you know, all the great work that our conference pla ...

重要新闻提示 港交所主席唐家成指出，2026年以来，已有24只新股上市，集资额超过870亿港元，目前排队上市的企 业有488家。港交所今年将全力推进各项工作，包括公布提升上市制度和T+1的咨询文件。 特区政府财经事务及库务局副局长陈浩濂在香港黄金交易所农历年黄金启市日暨2026年新春开市仪式上 表示，为进一步多元发展香港的国际金融业务，特区政府正全力推动香港成为国际黄金交易中心。陈浩 濂说，将以三年超越2000吨为拓展在港黄金仓储的目标，打造香港成为区域黄金储备枢纽。在推动大宗 商品交易方面，目前已有15个伦敦金属交易所认可的仓库在香港营运。港交所也会深化与广州期货交易 所及内地其他大宗商品市场的联通发展。 春节假期商品消费需求旺盛，智能眼镜、智能血糖仪等智能产品备受青睐 国家发展改革委将重点从四方面推动现代化首都都市圈建设 2026春节档档期总票房（含预售）突破39亿元；2026年年度电影总票房（含预售）突破60亿元 1. 据央视新闻2月20日报道，商务大数据显示，春节假期前四天，全国重点零售和餐饮企业日均销售额 较2025年假期前四天增长8.6%。 商品消费需求旺盛。以旧换新政策效应持续显现，截至2月19 ...

2月4日晚，东方港湾董事长但斌做客央视财经《投资大趋势》节目，分享了关于人工智能时代下的市场 投资见解。 投资作业本课代表整理了要点如下： 1、不学习，很可能错过一个时代。 回顾我们经历的电子硬件、互联网、移动互联网时代，每个时代都有重大机会。......腾讯，涨了六百多 (倍),网易涨了几千倍，这只是个案。从全球看，每个时代都涌现出许多上涨几千倍的公司。 从金融史看，过去100年，美国上市公司中，仅3%贡献了绝大部分利润，97%并不突出。 这个过程注定是少数公司创造价值，多数公司在毁灭价值。 2、当前对中国和全球经济而言，其实美国也一样，主要依靠人工智能、生物制药这类行业，比如商业 航天、即将上市的星链等。 这些新增长能否弥补其他领域的负向反馈?若能，经济就会蓬勃发展。因此，将资金投向这些方向，理 论上赢面更大。 3、对普通人和一般机构而言，错过一个时代的风险，远大于担心泡沫的风险。回顾过去几个时代，真 正赚到钱的人不多，很多人是错过了时代。 4、我个人判断，目前仍处于大发展之年。但为何很多人错失?因为存在泡沫的噪音。我视之为噪音，即 便今年下跌，也是噪音。 因为放在更长的周期里，今年可能只是蓄势之年。 5 ...

Core Insights - VeraDermics, TG-17, and Colombier Acquisition III went public on February 4, 2026, with significant stock price increases on their debut. Group 1: VeraDermics (MANE) - VeraDermics opened at $34 per share, a 100% increase from the offering price, and closed at $37.75, marking a 122.06% rise with a total market capitalization of $1.259 billion [1][2] - The company issued 15.08 million shares at $17 each, raising $256 million, which will be used for physician education, brand promotion, marketing, infrastructure, and other general corporate purposes [2] - VeraDermics is a late-stage biopharmaceutical company focused on developing innovative therapies for aesthetic and dermatological issues, currently working on an oral, non-hormonal therapy named VDPHL01 for treating PHL [2] Group 2: TG-17 (OBAI) - TG-17 opened at $20 per share, a 60.94% increase, and closed at $33, resulting in a 167.21% rise with a total market capitalization of $457 million [3][6] - The company went public through a direct listing without issuing new shares or raising capital [6] - TG-17 provides AI-driven personal safety services and operates in 28 countries, offering 14 types of monitoring and emergency coordination services [6] Group 3: Colombier Acquisition III (CLBRU) - Colombier Acquisition III issued 26 million units at $10 each, raising $260 million [7] - The company is a special purpose acquisition company (SPAC) initiated by Omeed Malik, focusing on sectors such as technology, advanced manufacturing, defense, energy, and digital infrastructure [7]

Core Viewpoint - The company, Changchun High-tech Industry (Group) Co., Ltd., announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received a clinical trial application acceptance notice from the National Medical Products Administration for the domestically produced drug, GenSci136, intended for the treatment of generalized myasthenia gravis (gMG) [1][4]. Group 1: Drug Information - Product Name: GenSci136, an injectable drug developed by Jinsai Pharmaceutical [1] - Application: Acceptance of clinical trial application for domestic production [1] - Indication: Treatment of generalized myasthenia gravis [1][2] Group 2: Disease Background - gMG is an autoimmune disease characterized by neuromuscular transmission disorders, with a global prevalence of approximately 12.4 per 100,000 people and an incidence rate in China of about 0.68 per 100,000 [2] - Traditional treatments include cholinesterase inhibitors, corticosteroids, and immunosuppressants, but about 20% of patients do not respond well to these therapies [2] Group 3: Drug Mechanism and Research - GenSci136 features a novel drug structure and dual-target mechanism, designed to enhance its blocking activity and prolong its half-life in the body [3] - Non-clinical pharmacology, pharmacokinetics, and toxicology studies indicate that GenSci136 has good efficacy and safety, potentially offering a better treatment option for patients with gMG in China [3] Group 4: Company Impact - Successful progress of the clinical trial application could help the company expand its business structure, optimize product offerings, and enhance its core competitiveness [4]

Core Viewpoint - Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, has had its clinical trial application for the domestically produced injectable GenSci136 accepted by the National Medical Products Administration, marking a significant step in the development of a new treatment for myasthenia gravis [1] Group 1: Product Development - GenSci136 is a Class 1 biological product designed to treat generalized myasthenia gravis, featuring a novel drug structure and a dual-target mechanism of action [1] - The drug aims to provide better treatment options for patients with myasthenia gravis in China [1] Group 2: Business Impact - The progress of this application is expected to broaden the company's business structure and enhance its core competitiveness [1] - The clinical trial process, however, still carries uncertainties that could affect the timeline and outcomes [1]

每经记者|章光日 每经编辑|何小桃 吴永久 1月30日早上，新诺威（SZ300765，市值546亿元）迎来新任总经理和新任董事会秘书，二人皆为"90后"。不过，资本市场对此反应并不友好，新诺威早 盘股价最大跌幅一度达到18%。而不久前，新诺威还发布了2025年年度业绩预亏公告，净利润较2024年同期下降416%至575%。 新任总经理和董秘皆为"90后" 1月30日，新诺威发布关于变更公司总经理、董事会秘书及证券事务代表的公告。该公告显示，姚兵申请辞去公司总经理职务，戴龙申请辞去公司董事会 秘书及证券事务代表职务，与此同时，公司董事会同意聘任戴龙担任公司总经理，同意聘任徐雯担任公司董事会秘书及证券事务代表。 而新诺威新任总经理戴龙和新任董事会秘书皆为"90后"。 戴龙1992年6月出生，本科学历，2016年12月加入新诺威，历任公司财务经理、证券事务代表、董事会秘书。目前，戴龙还担任新诺威的董事和财务总 监。新诺威2024年年报显示，尽管身兼数职，但戴龙2024年从公司获得的税前报酬总额仅为22.32万元。 徐雯1990年4月出生，硕士学历，从2024年5月开始担任新诺威的董事。不过，新诺威2024年年报显示 ...

Group 1 - New CEO and Secretary appointed at XinNuoWei, both born in the 1990s, leading to a negative market reaction with a stock price drop of up to 18% [1][10] - The company announced a significant expected net profit loss for 2025, projecting a decline of 416% to 575% compared to 2024 [1][12] - The new CEO, Dai Long, has been with the company since 2016 and previously held multiple roles, while the new Secretary, Xu Wen, has a master's degree and will also serve as a board member [2][7] Group 2 - XinNuoWei's main business focuses on biopharmaceuticals and functional foods, with recent developments in ADC, mRNA vaccines, and antibody drugs [12] - The projected net profit for 2025 is expected to be between -1.7 billion to -2.55 billion, marking a significant decline from a profit of 537.26 million in 2024 [12][13] - The decline in performance is attributed to increased R&D expenses, the acquisition of a controlling stake in a subsidiary, and reduced profit margins in the functional raw materials segment [14]

Core Viewpoint - Newnow (300765) has appointed a new general manager and board secretary, both born in the 1990s, but the market reacted negatively, with the stock price dropping by up to 18% in early trading. The company also announced a significant expected net profit decline for 2025, with a decrease of 416% to 575% compared to the same period in 2024 [1]. Group 1 - The new general manager, Dai Long, born in June 1992, has a bachelor's degree and joined Newnow in December 2016, holding multiple roles including financial manager, securities affairs representative, and board secretary [1]. - Despite holding several positions, Dai Long's pre-tax compensation for 2024 was only 223,200 yuan [1]. - Newnow's main business focuses on the research, production, and sales of biopharmaceuticals and functional foods and raw materials, with a focus on cutting-edge areas such as ADC, mRNA vaccines, and antibody drugs [1].

Core Viewpoint - Newnow's stock price dropped significantly following the announcement of new management, with a maximum decline of 18% on January 30, 2024, and a closing drop of 15.72%, resulting in a market capitalization of approximately 54.6 billion yuan [1][8]. Management Changes - Newnow appointed Dai Long as the new General Manager and Xu Wen as the new Secretary of the Board, both of whom are in their 30s [1][6]. - Former General Manager Yao Bing, who was born in May 1977, will continue to serve as the Chairman of the Board after stepping down [4]. - Dai Long, born in June 1992, has held various positions within the company since December 2016 and received a pre-tax salary of 223,200 yuan in 2024 [6][7]. - Xu Wen, born in April 1990, has a master's degree and received no salary from the company in 2024, although she earned compensation from related parties [6][7]. Financial Performance - Newnow's 2025 performance forecast indicates a net loss of 170 million to 255 million yuan, representing a decline of 416% to 575% compared to the same period in 2024 [9][10]. - The company also anticipates a non-recurring net loss of 210 million to 315 million yuan, a decrease of 596% to 844% from 2024 [9][10]. - The decline in performance is attributed to increased R&D expenses for several in-development products, the acquisition of minority stakes in a subsidiary, and reduced profit margins in the functional raw materials business [10]. Business Overview - Newnow's main business focuses on the research, production, and sales of biopharmaceuticals and functional foods, including areas such as ADC, mRNA vaccines, and antibody drugs [8]. - The company has experienced a significant decline in net profits over the past three years, with figures of 726 million yuan in 2022, 434 million yuan in 2023, and 53.726 million yuan in 2024 [10].